{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T22:17:22Z","timestamp":1793657842849,"version":"4.5.1"},"reference-count":134,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s12325-025-03293-6","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T06:40:41Z","timestamp":1754462441000},"page":"4797-4823","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The Feasibility and Impact of Implementing Interventions to Reduce Short-Acting \u03b22-Agonist Over-Reliance in Asthma: An Expert Opinion"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9868-9883","authenticated-orcid":false,"given":"Luis","family":"Nannini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaurbek","family":"Aisanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurtulu\u015f","family":"Aksu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashraf","family":"Alzaabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Ant\u00fanez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonora","family":"Ca\u00f1izares-Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Cohen-Todd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael G.","family":"Crooks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisham","family":"Farouk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suyapa Sosa","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pin-Kuei","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashraf","family":"Hatem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Truong","family":"Le Van Ngoc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kittipong","family":"Maneechotesuwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter Javier","family":"Mattarucco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Mpe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesc Xavier Moranta","family":"Ribas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas Javier","family":"V\u00e1zquez-Cort\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faisal","family":"Yunus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,6]]},"reference":[{"key":"3293_CR1","unstructured":"World Health Organization (WHO). Asthma - Key Facts. 2022. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/asthma. Accessed 29 Sep 2022."},{"key":"3293_CR2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40733-016-0029-3","volume":"3","author":"C Nunes","year":"2017","unstructured":"Nunes C, Pereira AM, Morais-Almeida M. Asthma costs and social impact. Asthma Res Pract. 2017;3:1.","journal-title":"Asthma Res Pract."},{"key":"3293_CR3","unstructured":"Global Asthma Network (GAN). The Global Asthma Report (2018). http:\/\/www.globalasthmareport.org. Accessed 29 Sep 2022."},{"key":"3293_CR4","doi-asserted-by":"crossref","first-page":"2101402","DOI":"10.1183\/13993003.01402-2021","volume":"59","author":"ED Bateman","year":"2022","unstructured":"Bateman ED, Price DB, Wang HC, Khattab A, Schonffeldt P, Catanzariti A, et al. Short-acting \u03b22-agonist prescriptions are associated with poor clinical outcomes of asthma: the multi-country, cross-sectional SABINA III study. Eur Respir J. 2022;59:2101402.","journal-title":"Eur Respir J"},{"key":"3293_CR5","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJM199202203260801","volume":"326","author":"WO Spitzer","year":"1992","unstructured":"Spitzer WO, Suissa S, Ernst P, Horwitz RI, Habbick B, Cockcroft D, et al. The use of beta-agonists and the risk of death and near death from asthma. N Engl J Med. 1992;326:501\u20136.","journal-title":"N Engl J Med"},{"key":"3293_CR6","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1164\/ajrccm.149.3.8118625","volume":"149","author":"S Suissa","year":"1994","unstructured":"Suissa S, Ernst P, Boivin JF, Horwitz RI, Habbick B, Cockroft D, et al. A cohort analysis of excess mortality in asthma and the use of inhaled beta-agonists. Am J Respir Crit Care Med. 1994;149:604\u201310.","journal-title":"Am J Respir Crit Care Med"},{"key":"3293_CR7","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/oxfordjournals.epirev.a017979","volume":"20","author":"N Pearce","year":"1998","unstructured":"Pearce N, Hensley MJ. Epidemiologic studies of beta agonists and asthma deaths. Epidemiol Rev. 1998;20:173\u201386.","journal-title":"Epidemiol Rev"},{"key":"3293_CR8","doi-asserted-by":"crossref","unstructured":"Al-Jahdali H, Wali S, Albanna AS, Al Harbi A, Allehebi R, Arwadi A, et al. Overprescription of short-acting \u03b22 -agonists among patients with asthma in Saudi Arabia: results from the SABINA III cohort study. Clin Respir J. 2022;16:812\u201325.","DOI":"10.1111\/crj.13553"},{"key":"3293_CR9","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40733-022-00085-5","volume":"8","author":"A Alzaabi","year":"2022","unstructured":"Alzaabi A, Al Busaidi N, Pradhan R, Shandy F, Ibrahim N, Ashtar M, et al. Over-prescription of short-acting \u03b22-agonists and asthma management in the Gulf region: a multicountry observational study. Asthma Res Pract. 2022;8:3.","journal-title":"Asthma Res Pract."},{"key":"3293_CR10","volume":"10","author":"JK Quint","year":"2022","unstructured":"Quint JK, Arnetorp S, Kocks JWH, Kupczyk M, Nuevo J, Plaza V, et al. Short-acting beta-2-agonist exposure and severe asthma exacerbations: SABINA findings from Europe and North America. J Allergy Clin Immunol Pract. 2022;10:2297\u2013309.e10.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"3293_CR11","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1016\/j.jfma.2022.05.014","volume":"121","author":"SY Shen","year":"2022","unstructured":"Shen SY, Chen CW, Liu TC, Wang CY, Chiu MH, Chen YJ, et al. SABA prescriptions and asthma management practices in patients treated by specialists in Taiwan: results from the SABINA III study. J Formos Med Assoc. 2022;121:2527\u201337.","journal-title":"J Formos Med Assoc"},{"key":"3293_CR12","doi-asserted-by":"crossref","unstructured":"Montero-Arias F, Garcia JCH, Gallego MP, Antila MA, Schonffeldt P, Mattarucco WJ, et al. Over-prescription of short-acting \u03b22-agonists is associated with poor asthma outcomes: results from the Latin American cohort of the SABINA III study. J Asthma. 2023;60:574\u201387.","DOI":"10.1080\/02770903.2022.2082305"},{"key":"3293_CR13","doi-asserted-by":"crossref","unstructured":"Khattab A, Madkour A, Ambaram A, Smith C, Muhwa CJ, Mecha JO, et al. Over-prescription of short-acting \u03b22-agonists is associated with poor asthma outcomes: results from the African cohort of the SABINA III study. Curr Med Res Opin. 2022;38:1983\u201395.","DOI":"10.1080\/03007995.2022.2100649"},{"key":"3293_CR14","doi-asserted-by":"crossref","unstructured":"Mortimer K, Reddel HK, Pitrez PM, Bateman ED. Asthma management in low and middle income countries: case for change. Eur Respir J. 2022;60:2103179.","DOI":"10.1183\/13993003.03179-2021"},{"key":"3293_CR15","doi-asserted-by":"crossref","first-page":"347","DOI":"10.2147\/IJGM.S147752","volume":"10","author":"VN Nguyen","year":"2017","unstructured":"Nguyen VN, Nguyen QN, Le An P, Chavannes NH. Implementation of GINA guidelines in asthma management by primary care physicians in Vietnam. Int J Gen Med. 2017;10:347\u201355.","journal-title":"Int J Gen Med."},{"key":"3293_CR16","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1067\/mai.2001.115653","volume":"107","author":"S Suissa","year":"2001","unstructured":"Suissa S, Ernst P. Inhaled corticosteroids: impact on asthma morbidity and mortality. J Allergy Clin Immunol. 2001;107:937\u201344.","journal-title":"J Allergy Clin Immunol"},{"key":"3293_CR17","doi-asserted-by":"crossref","unstructured":"O'Byrne P, Fabbri LM, Pavord ID, Papi A, Petruzzelli S, Lange P. Asthma progression and mortality: the role of inhaled corticosteroids. Eur Respir J. 2019;54:1900491.","DOI":"10.1183\/13993003.00491-2019"},{"key":"3293_CR18","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1056\/NEJM200008033430504","volume":"343","author":"S Suissa","year":"2000","unstructured":"Suissa S, Ernst P, Benayoun S, Baltzan M, Cai B. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med. 2000;343:332\u20136.","journal-title":"N Engl J Med"},{"key":"3293_CR19","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1136\/bmj.1.5800.585","volume":"1","author":"HM Brown","year":"1972","unstructured":"Brown HM, Storey G, George WH. Beclomethasone dipropionate: a new steroid aerosol for the treatment of allergic asthma. Br Med J. 1972;1:585\u201390.","journal-title":"Br Med J"},{"key":"3293_CR20","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1136\/bmj.4.5886.205","volume":"4","author":"SJ Cameron","year":"1973","unstructured":"Cameron SJ, Cooper EJ, Crompton GK, Hoare MV, Grant IW. Substitution of beclomethasone aerosol for oral prednisolone in the treatment of chronic asthma. Br Med J. 1973;4:205\u20137.","journal-title":"Br Med J"},{"key":"3293_CR21","doi-asserted-by":"crossref","unstructured":"Pauwels RA, Lofdahl CG, Postma DS, Tattersfield AE, O'Byrne P, Barnes PJ, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med. 1997;337:1405\u201311.","DOI":"10.1056\/NEJM199711133372001"},{"key":"3293_CR22","unstructured":"Global Initiative for Asthma. Global strategy for asthma management and prevention. 2024. https:\/\/ginasthma.org\/wp-content\/uploads\/2024\/05\/GINA-2024-Strategy-Report-24_05_22_WMS.pdf. Accessed May 30, 2024."},{"key":"3293_CR23","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1056\/NEJMoa1715274","volume":"378","author":"PM O'Byrne","year":"2018","unstructured":"O\u2019Byrne PM, FitzGerald JM, Bateman ED, Barnes PJ, Zhong N, Keen C, et al. Inhaled combined budesonide-formoterol as needed in mild asthma. N Engl J Med. 2018;378:1865\u201376.","journal-title":"N Engl J Med"},{"key":"3293_CR24","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1056\/NEJMoa1715275","volume":"378","author":"ED Bateman","year":"2018","unstructured":"Bateman ED, Reddel HK, O\u2019Byrne PM, Barnes PJ, Zhong N, Keen C, et al. As-needed budesonide-formoterol versus maintenance budesonide in mild asthma. N Engl J Med. 2018;378:1877\u201387.","journal-title":"N Engl J Med"},{"key":"3293_CR25","doi-asserted-by":"crossref","unstructured":"Crossingham I, Turner S, Ramakrishnan S, Fries A, Gowell M, Yasmin F, et al. Combination fixed-dose beta agonist and steroid inhaler as required for adults or children with mild asthma. Cochrane Database Syst Rev. 2021;5:CD013518.","DOI":"10.1002\/14651858.CD013518.pub2"},{"key":"3293_CR26","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S0140-6736(19)31948-8","volume":"394","author":"J Hardy","year":"2019","unstructured":"Hardy J, Baggott C, Fingleton J, Reddel HK, Hancox RJ, Harwood M, et al. Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRACTICAL): a 52-week, open-label, multicentre, superiority, randomised controlled trial. Lancet. 2019;394:919\u201328.","journal-title":"Lancet"},{"key":"3293_CR27","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1111\/j.1742-1241.2007.01338.x","volume":"61","author":"P Kuna","year":"2007","unstructured":"Kuna P, Peters MJ, Manjra AI, Jorup C, Naya IP, Martinez-Jimenez NE, et al. Effect of budesonide\/formoterol maintenance and reliever therapy on asthma exacerbations. Int J Clin Pract. 2007;61:725\u201336.","journal-title":"Int J Clin Pract"},{"key":"3293_CR28","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1185\/030079904X2051","volume":"20","author":"R Scicchitano","year":"2004","unstructured":"Scicchitano R, Aalbers R, Ukena D, Manjra A, Fouquert L, Centanni S, et al. Efficacy and safety of budesonide\/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma. Curr Med Res Opin. 2004;20:1403\u201318.","journal-title":"Curr Med Res Opin"},{"key":"3293_CR29","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1378\/chest.129.2.246","volume":"129","author":"KF Rabe","year":"2006","unstructured":"Rabe KF, Pizzichini E, Stallberg B, Romero S, Balanzat AM, Atienza T, et al. Budesonide\/formoterol in a single inhaler for maintenance and relief in mild-to-moderate asthma: a randomized, double-blind trial. Chest. 2006;129:246\u201356.","journal-title":"Chest"},{"key":"3293_CR30","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S2213-2600(20)30416-1","volume":"9","author":"PM O'Byrne","year":"2020","unstructured":"O\u2019Byrne PM, FitzGerald JM, Bateman ED, Barnes PJ, Zheng J, Gustafson P, et al. Effect of a single day of increased as-needed budesonide-formoterol use on short-term risk of severe exacerbations in patients with mild asthma: a post-hoc analysis of the SYGMA 1 study. Lancet Respir Med. 2020;9:149\u201358.","journal-title":"Lancet Respir Med"},{"key":"3293_CR31","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1901963","volume":"380","author":"R Beasley","year":"2019","unstructured":"Beasley R, Holliday M, Reddel HK, Braithwaite I, Ebmeier S, Hancox RJ, et al. Controlled trial of budesonide-formoterol as needed for mild asthma. N Engl J Med. 2019;380:2020\u201330.","journal-title":"N Engl J Med"},{"key":"3293_CR32","unstructured":"Global Initiative for Asthma. Global strategy for asthma management and prevention. 2019. http:\/\/ginasthma.org\/. Accessed 29 Sep 2022."},{"key":"3293_CR33","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1111\/resp.13804","volume":"25","author":"CR Jenkins","year":"2020","unstructured":"Jenkins CR, Bateman ED, Sears MR, O\u2019Byrne PM. What have we learnt about asthma control from trials of budesonide\/formoterol as maintenance and reliever? Respirology. 2020;25:804\u201315.","journal-title":"Respirology"},{"key":"3293_CR34","doi-asserted-by":"crossref","unstructured":"Rogliani P, Ritondo BL, Ora J, Cazzola M, Calzetta L. SMART and as-needed therapies in mild-to-severe asthma: a network meta-analysis. Eur Respir J. 2020;56:2000625.","DOI":"10.1183\/13993003.00625-2020"},{"key":"3293_CR35","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S0140-6736(21)00458-X","volume":"397","author":"J Meghji","year":"2021","unstructured":"Meghji J, Mortimer K, Agusti A, Allwood BW, Asher I, Bateman ED, et al. Improving lung health in low-income and middle-income countries: from challenges to solutions. Lancet. 2021;397:928\u201340.","journal-title":"Lancet"},{"key":"3293_CR36","doi-asserted-by":"crossref","first-page":"105","DOI":"10.25259\/JPATS_37_2022","volume":"3","author":"K Mortimer","year":"2022","unstructured":"Mortimer K, Masekela R, Ozoh OB, Bateman ED, Nantanda R, Yorganc\u0131o\u011flu AA, et al. The reality of managing asthma in sub-Saharan Africa \u2013 priorities and strategies for improving care. J Pan Afr Thorac Soc. 2022;3:105\u201320.","journal-title":"J Pan Afr Thorac Soc."},{"key":"3293_CR37","doi-asserted-by":"crossref","first-page":"4190","DOI":"10.1007\/s12325-020-01444-5","volume":"37","author":"CI Bloom","year":"2020","unstructured":"Bloom CI, Cabrera C, Arnetorp S, Coulton K, Nan C, van der Valk RJP, et al. Asthma-related health outcomes associated with short-acting beta2-agonist inhaler use: an observational UK study as part of the SABINA global program. Adv Ther. 2020;37:4190\u2013208.","journal-title":"Adv Ther"},{"key":"3293_CR38","first-page":"S26","volume":"76","author":"AJK Wilkinson","year":"2021","unstructured":"Wilkinson AJK, Menzies-Gow A, Sawyer M, Bell JP, Xu Y, Budgen N, et al. An assessment of short-acting \u03b22-agonist (SABA) use and subsequent greenhouse gas (GHG) emissions in five European countries and the consequence of their potential overuse for asthma in the UK. Thorax. 2021;76:S26.","journal-title":"Thorax"},{"key":"3293_CR39","doi-asserted-by":"publisher","unstructured":"Wilkinson A, Maslova E, Janson C, Radhakrishnan V, Quint JK, Budgen N, et al. Greenhouse gas emissions associated with asthma care in the UK: results from SABINA CARBON. Eur Respir J. 2021;58:OA76. https:\/\/doi.org\/10.1183\/13993003.congress-2021.OA76.","DOI":"10.1183\/13993003.congress-2021.OA76"},{"key":"3293_CR40","doi-asserted-by":"crossref","first-page":"00685","DOI":"10.1183\/23120541.00685-2022","volume":"9","author":"MG Crooks","year":"2023","unstructured":"Crooks MG, Crowther L, Cummings H, Cohen J, Huang C, Pitel L, et al. Improving asthma care through implementation of the SENTINEL program: findings from the pilot site. ERJ Open Res. 2023;9:00685\u20132022.","journal-title":"ERJ Open Res."},{"key":"3293_CR41","doi-asserted-by":"crossref","unstructured":"Crowther L, Pearson M, Cummings H, Crooks MG. Towards codesign in respiratory care: development of an implementation-ready intervention to improve guideline-adherent adult asthma care across primary and secondary care settings (The SENTINEL Project). BMJ Open Respir Res. 2022;9:e001155.","DOI":"10.1136\/bmjresp-2021-001155"},{"key":"3293_CR42","unstructured":"Yorkshire & Humber AHSN. New NHS collaboration supports optimisation of asthma management. https:\/\/www.yhahsn.org.uk\/news\/new-nhs-collaboration-supports-optimisation-of-asthma-management\/. Accessed 29 Sep 2022."},{"key":"3293_CR43","unstructured":"OpenPrescribing. Explore England's prescribing data. https:\/\/openprescribing.net\/. Accessed 29 Sep 2022."},{"key":"3293_CR44","unstructured":"National Health Service (NHS). Primary care. https:\/\/digital.nhs.uk\/data-and-information\/areas-of-interest\/primary-care. Accessed 29 Sep 2022."},{"key":"3293_CR45","unstructured":"SENTINEL Plus. https:\/\/sentinelplus.info\/. Accessed 29 Sep 2022."},{"key":"3293_CR46","unstructured":"Openprescribing. Holderness Primary Care Home PCN. https:\/\/openprescribing.net\/pcn\/U64827\/measures\/?tags=respiratory. Accessed 29 Sep 2022."},{"key":"3293_CR47","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1164\/rccm.200903-0450ST","volume":"181","author":"JM Kahn","year":"2010","unstructured":"Kahn JM, Scales DC, Au DH, Carson SS, Curtis JR, Dudley RA, et al. An official American Thoracic Society policy statement: pay-for-performance in pulmonary, critical care, and sleep medicine. Am J Respir Crit Care Med. 2010;181:752\u201361.","journal-title":"Am J Respir Crit Care Med"},{"key":"3293_CR48","first-page":"8943972","volume":"2019","author":"K Kyeremanteng","year":"2019","unstructured":"Kyeremanteng K, Robidoux R, D\u2019Egidio G, Fernando SM, Neilipovitz D. An analysis of pay-for-performance schemes and their potential impacts on health systems and outcomes for patients. Crit Care Res Pract. 2019;2019:8943972.","journal-title":"Crit Care Res Pract."},{"key":"3293_CR49","unstructured":"National Health Insurance Administration. https:\/\/www.nhi.gov.tw\/English\/Content_List.aspx?n=7B24D0240347DAA8&topn=BCB2B0D2433F6491. Accessed 29 Sep 2022."},{"key":"3293_CR50","unstructured":"Ministry of Health and Welfare. Taiwan health and welfare report. 2017. https:\/\/www.mohw.gov.tw\/cp-137-40301-2.html. Accessed 29 Sep 2022."},{"key":"3293_CR51","first-page":"S54","volume":"21","author":"L Mesana","year":"2018","unstructured":"Mesana L, Cheung L, Syed IA, Gauthier A, Pruce D. Value-based health care in Asia: outcomes from Taiwan\u2019s pay-for-performance programs. Value Health. 2018;21:S54.","journal-title":"Value Health."},{"key":"3293_CR52","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41533-021-00231-1","volume":"31","author":"CY Wang","year":"2021","unstructured":"Wang CY, Lai CC, Wang YH, Wang HC. The prevalence and outcome of short-acting beta2-agonists overuse in asthma patients in Taiwan. NPJ Prim Care Respir Med. 2021;31:19.","journal-title":"NPJ Prim Care Respir Med."},{"key":"3293_CR53","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1111\/1475-6773.13174","volume":"54","author":"TT Chen","year":"2019","unstructured":"Chen TT, Yang JJ, Hsueh YA, Wang V. The effects of a schizophrenia pay-for-performance program on patient outcomes in Taiwan. Health Serv Res. 2019;54:1119\u201325.","journal-title":"Health Serv Res"},{"key":"3293_CR54","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.2147\/COPD.S329454","volume":"16","author":"SL Cheng","year":"2021","unstructured":"Cheng SL, Li YR, Huang N, Yu CJ, Wang HC, Lin MC, et al. Effectiveness of nationwide COPD pay-for-performance program on COPD exacerbations in Taiwan. Int J Chron Obstruct Pulmon Dis. 2021;16:2869\u201381.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"3293_CR55","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1093\/ndt\/gfw401","volume":"32","author":"HM Hsieh","year":"2017","unstructured":"Hsieh HM, Lin MY, Chiu YW, Wu PH, Cheng LJ, Jian FS, et al. Economic evaluation of a pre-ESRD pay-for-performance programme in advanced chronic kidney disease patients. Nephrol Dial Transpl. 2017;32:1184\u201394.","journal-title":"Nephrol Dial Transpl"},{"key":"3293_CR56","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1097\/MLR.0000000000000598","volume":"54","author":"YC Huang","year":"2016","unstructured":"Huang YC, Lee MC, Chou YJ, Huang N. Disease-specific pay-for-performance programs: do the P4P effects differ between diabetic patients with and without multiple chronic conditions? Med Care. 2016;54:977\u201383.","journal-title":"Med Care"},{"issue":"Suppl 2","key":"3293_CR57","doi-asserted-by":"crossref","first-page":"S122","DOI":"10.1016\/j.jfma.2019.08.011","volume":"118","author":"IT Lee","year":"2019","unstructured":"Lee IT, Hsu CC, Sheu WH, Su SL, Wu YL, Lin SY. Pay-for-performance for shared care of diabetes in Taiwan. J Formos Med Assoc. 2019;118(Suppl 2):S122\u20139.","journal-title":"J Formos Med Assoc"},{"key":"3293_CR58","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.healthpol.2016.09.014","volume":"120","author":"TY Lin","year":"2016","unstructured":"Lin TY, Chen CY, Huang YT, Ting MK, Huang JC, Hsu KH. The effectiveness of a pay for performance program on diabetes care in Taiwan: a nationwide population-based longitudinal study. Health Policy. 2016;120:1313\u201321.","journal-title":"Health Policy"},{"key":"3293_CR59","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1001\/jamaoncol.2016.4549","volume":"3","author":"CJ Wang","year":"2017","unstructured":"Wang CJ, Cheng SH, Wu JY, Lin YP, Kao WH, Lin CL, et al. Association of a bundled-payment program with cost and outcomes in full-cycle breast cancer care. JAMA Oncol. 2017;3:327\u201334.","journal-title":"JAMA Oncol"},{"key":"3293_CR60","volume":"11","author":"HJ Chen","year":"2016","unstructured":"Chen HJ, Huang N, Chen LS, Chou YJ, Li CP, Wu CY, et al. Does pay-for-performance program increase providers adherence to guidelines for managing hepatitis B and hepatitis C virus infection in Taiwan? PLoS ONE. 2016;11:e0161002.","journal-title":"PLoS ONE"},{"key":"3293_CR61","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/MLR.0b013e31822d5d36","volume":"50","author":"SH Cheng","year":"2012","unstructured":"Cheng SH, Lee TT, Chen CC. A longitudinal examination of a pay-for-performance program for diabetes care: evidence from a natural experiment. Med Care. 2012;50:109\u201316.","journal-title":"Med Care"},{"key":"3293_CR62","doi-asserted-by":"crossref","unstructured":"Fu P-K, Yu T-H. The effect of implementing asthma Pay-for-Performance (P4P) on healthcare outcomes in Taiwan: a nationwide retrospective cohort analysis. Eur Respir J. 2024;64:PA742.","DOI":"10.1183\/13993003.congress-2024.PA742"},{"key":"3293_CR63","unstructured":"The International Primary Care Respiratory Group (IPCRG). Asthma Right Care case study. How Spanish pharmacists have improved their role in asthma management from supplying SABA without restriction to prescription-only dispensing. 2021. https:\/\/www.ipcrg.org\/sites\/ipcrg\/files\/content\/attachments\/2021-09-13\/SABA%20OTC%20Case%20Study%20-%20FINAL.pdf. Accessed Mar 05, 2022."},{"key":"3293_CR64","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1080\/02770903.2020.1837157","volume":"59","author":"D Shlomi","year":"2022","unstructured":"Shlomi D, Oberman B, Katz I. Short-acting bronchodilators purchase as a marker for asthma control. J Asthma. 2022;59:206\u201312.","journal-title":"J Asthma"},{"key":"3293_CR65","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1136\/bmj.306.6891.1514","volume":"306","author":"P Gibson","year":"1993","unstructured":"Gibson P, Henry D, Francis L, Cruickshank D, Dupen F, Higginbotham N, et al. Association between availability of non-prescription beta 2 agonist inhalers and undertreatment of asthma. BMJ. 1993;306:1514\u20138.","journal-title":"BMJ"},{"key":"3293_CR66","doi-asserted-by":"crossref","unstructured":"Williams S, Correia de Sousa J, Khoo EM, Ghedira H, Mak V, Martinez Vazquez M, et al. How to make Asthma Right Care \u2018easy' in primary care: learnings from the 2023 Asthma Right Care Summit. NPJ Prim Care Respir Med. 2024;34:4.","DOI":"10.1038\/s41533-024-00366-x"},{"key":"3293_CR67","doi-asserted-by":"publisher","first-page":"116","DOI":"10.5334\/ijic.ICIC21279","volume":"22","author":"M V\u00e1zquez","year":"2021","unstructured":"V\u00e1zquez M. Asthma Right Care Global movement: adopting new strategies to get a large-scale change in asthma management. Int J Integr Care. 2021;22:116. https:\/\/doi.org\/10.5334\/ijic.ICIC21279.","journal-title":"Int J Integr Care"},{"key":"3293_CR68","unstructured":"Alianza contra el asma (Alliance against asthma). https:\/\/alianzacontraelasma.sefac.org\/. Accessed Mar 05, 2022."},{"key":"3293_CR69","unstructured":"Business Federation of Spanish Pharmacists. Observatory of Medicine February 2018. https:\/\/isanidad.com\/wp-content\/uploads\/2018\/04\/Observatorio-del-Medicamento_Febrero.pdf. Accessed 29 Sep 2022."},{"key":"3293_CR70","unstructured":"Business Federation of Spanish Pharmacists. Observatory of Medicine February 2021. https:\/\/fefe.com\/wp-content\/uploads\/2021\/04\/Obs.-Febrero-2021-.pdf. Accessed 29 Sep 2022."},{"key":"3293_CR71","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1590\/S1806-37132009000700004","volume":"35","author":"GJ Rodrigo","year":"2009","unstructured":"Rodrigo GJ, Plaza V, Bellido-Casado J, Neffen H, Bazus MT, Levy G, et al. The study of severe asthma in Latin America and Spain (1994\u20132004): characteristics of patients hospitalized with acute severe asthma. J Bras Pneumol. 2009;35:635\u201344.","journal-title":"J Bras Pneumol"},{"key":"3293_CR72","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2020.100113","volume":"13","author":"MB Alith","year":"2020","unstructured":"Alith MB, Gazzotti MR, Nascimento OA, Jardim JR. Impact of asthma control on different age groups in five Latin American countries. World Allergy Organ J. 2020;13:100113.","journal-title":"World Allergy Organ J"},{"key":"3293_CR73","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.vhri.2014.06.007","volume":"5","author":"LS Gold","year":"2014","unstructured":"Gold LS, Montealegre F, Allen-Ramey FC, Jardim J, Sansores R, Sullivan SD. Asthma control and cost in Latin America. Value Health Reg Issues. 2014;5:25\u20138.","journal-title":"Value Health Reg Issues."},{"key":"3293_CR74","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1939-4551-6-19","volume":"6","author":"JF Maspero","year":"2013","unstructured":"Maspero JF, Jardim JR, Aranda A, Tassinari CP, Gonzalez-Diaz SN, Sansores RH, et al. Insights, attitudes, and perceptions about asthma and its treatment: findings from a multinational survey of patients from Latin America. World Allergy Organ J. 2013;6:19.","journal-title":"World Allergy Organ J"},{"key":"3293_CR75","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1590\/S1020-49892005000300007","volume":"17","author":"H Neffen","year":"2005","unstructured":"Neffen H, Fritscher C, Schacht FC, Levy G, Chiarella P, Soriano JB, et al. Asthma control in Latin America: the Asthma Insights and Reality in Latin America (AIRLA) survey. Rev Panam Salud Publica. 2005;17:191\u20137.","journal-title":"Rev Panam Salud Publica"},{"key":"3293_CR76","doi-asserted-by":"crossref","first-page":"2110706","DOI":"10.1080\/20018525.2022.2110706","volume":"9","author":"LJ Nannini","year":"2022","unstructured":"Nannini LJ, Neumayer NS, Brandan N, Fernandez OM, Flores DM. Asthma-related hospitalizations after implementing SABA-free asthma management with a maintenance and anti-inflammatory reliever regimen. Eur Clin Respir J. 2022;9:2110706.","journal-title":"Eur Clin Respir J."},{"key":"3293_CR77","first-page":"41","volume":"9","author":"GJ Rodrigo","year":"2009","unstructured":"Rodrigo GJ, Neffen H, Nannini LJ, Pi\u00f1eyro L, Gen\u00e9 R, Plaza V. Hospitalizaciones por asma aguda durante el per\u00edodo 1994\u20132004 en Argentina y Uruguay: El estudio EAGLE. Rev Am Med Resp. 2009;9:41\u20138.","journal-title":"Rev Am Med Resp."},{"key":"3293_CR78","first-page":"024","volume":"5","author":"JL Nannini","year":"2019","unstructured":"Nannini JL, Neumayer NS, Fern\u00e1ndez OM, Flores DM. Outpatient asthma management without rescue bronchodilators? J Pulm Med Respir Res. 2019;5:024.","journal-title":"J Pulm Med Respir Res."},{"key":"3293_CR79","doi-asserted-by":"crossref","unstructured":"Nannini LJ, Neumayer N, Brandan N, Fernandez O. Bronchodilator responsiveness testing with inhaled budesonide\/formoterol in asthma. Poster #31741 presented at Eur Respir Soc 2022.","DOI":"10.1183\/13993003.congress-2022.483"},{"key":"3293_CR80","doi-asserted-by":"crossref","unstructured":"Nannini LJ, Brandan N, Fernandez O, Chirino G, Zuccarino N. SABA-free asthma management challenged by REFER ID asthma questionnaire. Poster #31744 presented at Eur Respir Soc 2022.","DOI":"10.1183\/13993003.congress-2022.486"},{"key":"3293_CR81","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41533-022-00296-6","volume":"32","author":"M Beekman","year":"2022","unstructured":"Beekman M, Hales J, Al-Ahmad M, Del Olmo R, Tan TL. Breaking the vicious circle-the Asthma Referral Identifier (ReferID) tool. NPJ Prim Care Respir Med. 2022;32:40.","journal-title":"NPJ Prim Care Respir Med."},{"key":"3293_CR82","doi-asserted-by":"crossref","first-page":"969","DOI":"10.2147\/CEOR.S331499","volume":"13","author":"K Al Mazrouei","year":"2021","unstructured":"Al Mazrouei K, Almannaei AI, Nur FM, Bachnak N, Alzaabi A. Direct and indirect costs of asthma burden in Abu Dhabi: a retrospective analysis of insurance claims data from 2015 to 2018. Clinicoecon Outcomes Res. 2021;13:969\u201380.","journal-title":"Clinicoecon Outcomes Res."},{"key":"3293_CR83","doi-asserted-by":"crossref","unstructured":"Mahboub BHH, Shendi FRSMA, Safarini BK, AbdulAziz MF, Mustafa GM, Prakash V. Cost of asthma in Dubai, United Arab Emirates (UAE). J Pulm Resp Med. 2013;3:1000146.","DOI":"10.4172\/2161-105X.1000146"},{"key":"3293_CR84","doi-asserted-by":"crossref","first-page":"217","DOI":"10.4103\/1817-1737.69109","volume":"5","author":"BHH Mahboub","year":"2010","unstructured":"Mahboub BHH, Santhakumar S, Soriano JB, Pawankar R. Asthma insights and reality in the United Arab Emirates. Ann Thorac Med. 2010;5:217\u201321.","journal-title":"Ann Thorac Med."},{"key":"3293_CR85","first-page":"1015","volume":"13","author":"M Khadadah","year":"2009","unstructured":"Khadadah M, Mahboub B, Al-Busaidi NH, Sliman N, Soriano JB, Bahous J. Asthma insights and reality in the Gulf and the near East. Int J Tuberc Lung Dis. 2009;13:1015\u201322.","journal-title":"Int J Tuberc Lung Dis"},{"key":"3293_CR86","doi-asserted-by":"crossref","first-page":"4","DOI":"10.4103\/atm.ATM_697_20","volume":"16","author":"MS Al-Moamary","year":"2021","unstructured":"Al-Moamary MS, Alhaider SA, Alangari AA, Idrees MM, Zeitouni MO, Al Ghobain MO, et al. The Saudi Initiative for Asthma - 2021 update: guidelines for the diagnosis and management of asthma in adults and children. Ann Thorac Med. 2021;16:4\u201356.","journal-title":"Ann Thorac Med."},{"key":"3293_CR87","unstructured":"Ministry of Public Health Qatar. National clinical guidelines, The diagnosis and management of asthma in adults. https:\/\/www.moph.gov.qa\/_layouts\/download.aspx?SourceUrl=\/Admin\/Lists\/ClinicalGuidelinesAttachments\/Attachments\/18\/The%20Diagnosis%20and%20Management%20of%20Asthma%20in%20Adults.pdf. Accessed Oct 12, 2022."},{"key":"3293_CR88","unstructured":"Sultanate of Oman. Guidelines for management of asthma. https:\/\/www.moh.gov.om\/documents\/272928\/1314763\/Guidelines+for+management+of+Asthma+Second+edition+2009+%281%29.pdf\/c5e8ff0c-d937-4c57-bc2b-d225c26be727. Accessed Oct 12, 2022."},{"key":"3293_CR89","doi-asserted-by":"crossref","unstructured":"Al Busaidi N, Alweqayyan A, Al Zaabi A, Mahboub B, Al-Huraish F, Hameed M, et al. Gulf asthma diagnosis and management in adults: expert review and recommendations. Open Respir Med J. 2022;16:e187430642205230.","DOI":"10.2174\/18743064-v16-e2205230"},{"key":"3293_CR90","unstructured":"Emirates Thoracic Society (ETS). Algorithm for the management of adult asthma in the emergency department. https:\/\/www.etsociety.ae\/wp-content\/uploads\/2021\/03\/V9-Protocol_for_management_of_adult_asthma_AH.pdf. Accessed 29 Sep 2022."},{"key":"3293_CR91","doi-asserted-by":"crossref","first-page":"71","DOI":"10.4103\/atm.atm_469_21","volume":"17","author":"MO Zeitouni","year":"2022","unstructured":"Zeitouni MO, Al-Moamary MS, Coussa ML, Riachy M, Mahboub B, AlHuraish F, et al. Challenges and recommendations for the management of asthma in the Middle East and Africa. Ann Thorac Med. 2022;17:71\u201380.","journal-title":"Ann Thorac Med"},{"key":"3293_CR92","doi-asserted-by":"crossref","DOI":"10.5334\/ijic.1206","volume":"13","author":"R Bengoa","year":"2013","unstructured":"Bengoa R. Transforming health care: an approach to system-wide implementation. Int J Integr Care. 2013;13:e039.","journal-title":"Int J Integr Care"},{"key":"3293_CR93","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s40746-015-0026-4","volume":"1","author":"J Lavelle","year":"2015","unstructured":"Lavelle J, Schast A, Keren R. Standardizing care processes and improving quality using pathways and continuous quality improvement. Curr Treat Options Peds. 2015;1:347\u201358.","journal-title":"Curr Treat Options Peds"},{"key":"3293_CR94","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1332\/174426419X15552999451313","volume":"15","author":"L Locock","year":"2019","unstructured":"Locock L, Boaz A. Drawing straight lines along blurred boundaries: qualitative research, patient and public involvement in medical research, co-production and co-design. Evidence Policy. 2019;15:409\u201322.","journal-title":"Evidence Policy"},{"key":"3293_CR95","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1136\/qshc.2005.016527","volume":"15","author":"P Bate","year":"2006","unstructured":"Bate P, Robert G. Experience-based design: from redesigning the system around the patient to co-designing services with the patient. Qual Saf Health Care. 2006;15:307\u201310.","journal-title":"Qual Saf Health Care"},{"key":"3293_CR96","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s40814-020-00634-w","volume":"6","author":"N Pearson","year":"2020","unstructured":"Pearson N, Naylor PJ, Ashe MC, Fernandez M, Yoong SL, Wolfenden L. Guidance for conducting feasibility and pilot studies for implementation trials. Pilot Feasibility Stud. 2020;6:167.","journal-title":"Pilot Feasibility Stud"},{"key":"3293_CR97","unstructured":"American Academy of Family Physicians (AAFP). Basics of quality improvement. https:\/\/www.aafp.org\/family-physician\/practice-and-career\/managing-your-practice\/quality-improvement-basics.html. Accessed 29 Sep 2022."},{"key":"3293_CR98","doi-asserted-by":"crossref","first-page":"578","DOI":"10.4239\/wjd.v12.i5.578","volume":"12","author":"TT Chen","year":"2021","unstructured":"Chen TT, Oldenburg B, Hsueh YS. Chronic care model in the diabetes pay-for-performance program in Taiwan: benefits, challenges and future directions. World J Diabetes. 2021;12:578\u201389.","journal-title":"World J Diabetes"},{"key":"3293_CR99","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1475-6773.2010.01182.x","volume":"46","author":"TT Chen","year":"2011","unstructured":"Chen TT, Chung KP, Lin IC, Lai MS. The unintended consequence of diabetes mellitus pay-for-performance (P4P) program in Taiwan: are patients with more comorbidities or more severe conditions likely to be excluded from the P4P program? Health Serv Res. 2011;46:47\u201360.","journal-title":"Health Serv Res"},{"key":"3293_CR100","unstructured":"World Health Organization (WHO). WHO framework for meaningful engagement of people living with noncommunicable diseases, and mental health and neurological conditions. https:\/\/www.who.int\/publications\/i\/item\/9789240073074. Accessed Jul 04, 2024."},{"key":"3293_CR101","unstructured":"The International Primary Care Respiratory Group (IPCRG). Reliever reliance test. https:\/\/www.ipcrg.org\/sites\/ipcrg\/files\/content\/attachments\/2021-11-29\/Reliever%20Reliance%20Test%20English.pdf. Accessed Mar 05, 2022."},{"key":"3293_CR102","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1034\/j.1399-3003.1999.14d30.x","volume":"14","author":"MA de Oliveira","year":"1999","unstructured":"de Oliveira MA, Faresin SM, Bruno VF, de Bittencourt AR, Fernandes AL. Evaluation of an educational programme for socially deprived asthma patients. Eur Respir J. 1999;14:908\u201314.","journal-title":"Eur Respir J"},{"key":"3293_CR103","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2466-6-13","volume":"6","author":"MR Partridge","year":"2006","unstructured":"Partridge MR, van der Molen T, Myrseth SE, Busse WW. Attitudes and actions of asthma patients on regular maintenance therapy: the INSPIRE study. BMC Pulm Med. 2006;6:13.","journal-title":"BMC Pulm Med"},{"key":"3293_CR104","first-page":"93","volume":"8","author":"D Price","year":"2015","unstructured":"Price D, David-Wang A, Cho SH, Ho JC, Jeong JW, Liam CK, et al. Time for a new language for asthma control: results from REALISE Asia. J Asthma Allergy. 2015;8:93\u2013103.","journal-title":"J Asthma Allergy"},{"key":"3293_CR105","doi-asserted-by":"crossref","first-page":"14009","DOI":"10.1038\/npjpcrm.2014.9","volume":"24","author":"D Price","year":"2014","unstructured":"Price D, Fletcher M, van der Molen T. Asthma control and management in 8,000 European patients: the REcognise Asthma and LInk to Symptoms and Experience (REALISE) survey. NPJ Prim Care Respir Med. 2014;24:14009.","journal-title":"NPJ Prim Care Respir Med"},{"key":"3293_CR106","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1164\/rccm.200906-0907OC","volume":"181","author":"SR Wilson","year":"2010","unstructured":"Wilson SR, Strub P, Buist AS, Knowles SB, Lavori PW, Lapidus J, et al. Shared treatment decision making improves adherence and outcomes in poorly controlled asthma. Am J Respir Crit Care Med. 2010;181:566\u201377.","journal-title":"Am J Respir Crit Care Med"},{"key":"3293_CR107","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1542\/peds.2005-1055","volume":"117","author":"MD Cabana","year":"2006","unstructured":"Cabana MD, Slish KK, Evans D, Mellins RB, Brown RW, Lin X, et al. Impact of physician asthma care education on patient outcomes. Pediatrics. 2006;117:2149\u201357.","journal-title":"Pediatrics"},{"key":"3293_CR108","doi-asserted-by":"crossref","unstructured":"Nwaru BI, Ekstrom M, Hasvold P, Wiklund F, Telg G, Janson C. Overuse of short-acting \u03b22-agonists in asthma is associated with increased risk of exacerbation and mortality: a nationwide cohort study of the global SABINA programme. Eur Respir J. 2020;55:1901872.","DOI":"10.1183\/13993003.01872-2019"},{"key":"3293_CR109","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1080\/13696998.2019.1642899","volume":"22","author":"GH Elsisi","year":"2019","unstructured":"Elsisi GH, Carapinha J, Amin W, Thabet E, Elafify S, Amin M, et al. A budget impact analysis of budesonide\/formoterol in patients with mild asthma in Egypt. J Med Econ. 2019;22:1047\u201354.","journal-title":"J Med Econ"},{"key":"3293_CR110","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2020.106079","volume":"171","author":"JM FitzGerald","year":"2020","unstructured":"FitzGerald JM, Arnetorp S, Smare C, Gibson D, Coulton K, Hounsell K, et al. The cost-effectiveness of as-needed budesonide\/formoterol versus low-dose inhaled corticosteroid maintenance therapy in patients with mild asthma in the UK. Respir Med. 2020;171:106079.","journal-title":"Respir Med"},{"key":"3293_CR111","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s13223-021-00610-w","volume":"17","author":"M Sadatsafavi","year":"2021","unstructured":"Sadatsafavi M, FitzGerald JM, O\u2019Byrne PM, Soliman M, Sriskandarajah N, Vicente C, et al. The cost-effectiveness of as-needed budesonide-formoterol versus low-dose inhaled corticosteroid maintenance therapy in patients with mild asthma in Canada. Allergy Asthma Clin Immunol. 2021;17:108.","journal-title":"Allergy Asthma Clin Immunol"},{"key":"3293_CR112","unstructured":"US Food & Drug Administration. FDA approves drug combination treatment for adults with asthma. https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-drug-combination-treatment-adults-asthma. Accessed May 30, 2024."},{"key":"3293_CR113","unstructured":"Nebraska antimicrobial stewardship assessment and promotion program. CDC Updates Core Elements of Hospital Antibiotic Stewardship Programs. https:\/\/asap.nebraskamed.com\/2019\/12\/02\/cdc-updates-core-elements-of-hospital-antibiotic-stewardship-programs\/. Accessed 29 Sep 2022."},{"key":"3293_CR114","unstructured":"Pan American Health Organization. Recommendations for Implementing Antimicrobial Stewardship Programs in Latin America and the Caribbean: Manual for Public Health Decision-Makers. https:\/\/iris.paho.org\/handle\/10665.2\/49645. Accessed 29 Sep 2022."},{"key":"3293_CR115","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3109\/14659891.2011.615002","volume":"18","author":"RJ Cooper","year":"2013","unstructured":"Cooper RJ. Over-the-counter medicine abuse - a review of the literature. J Subst Use. 2013;18:82\u2013107.","journal-title":"J Subst Use"},{"key":"3293_CR116","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41533-024-00397-4","volume":"34","author":"D Price","year":"2024","unstructured":"Price D, Beekman MJHI, Mattarucco WJ, Barriga-Acevedo RM, Wang HC, Diaz DV, et al. Over-the-counter short-acting \u03b22-agonist purchase and asthma-related health outcomes: a post hoc analysis of the SABINA III study. NPJ Prim Care Respir Med. 2024;34:34.","journal-title":"NPJ Prim Care Respir Med"},{"key":"3293_CR117","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1177\/1715163516660572","volume":"149","author":"JI MacKinnon","year":"2016","unstructured":"MacKinnon JI. Tighter regulations needed for over-the-counter codeine in Canada. Can Pharm J (Ott). 2016;149:322\u20134.","journal-title":"Can Pharm J (Ott)"},{"key":"3293_CR118","unstructured":"Global Alliance against Chronic Respiratory Diseases (GARD). https:\/\/www.who.int\/groups\/global-alliance-against-chronic-respiratory-diseases-(gard). Accessed 29 Sep 2022."},{"key":"3293_CR119","unstructured":"World Health Organization (WHO). Chronic respiratory diseases (GARD). https:\/\/www.who.int\/health-topics\/chronic-respiratory-diseases#tab=tab_1. Accessed 29 Sep 2022."},{"key":"3293_CR120","unstructured":"World Health Organization (WHO). Global alliance against chronic respiratory diseases. Action plan 2008\u20132013. http:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/43984\/9789241597203_eng.pdf?sequence=1. Accessed 29 Sep 2022."},{"key":"3293_CR121","first-page":"213","volume":"58","author":"A Yorgancioglu","year":"2010","unstructured":"Yorgancioglu A, Yardim N, Ergun P, Karlikaya C, Kocabas A, Mungan D, et al. Integration of GARD Turkey national program with other non-communicable diseases plans in Turkey. Tuberk Toraks. 2010;58:213\u201328.","journal-title":"Tuberk Toraks"},{"key":"3293_CR122","doi-asserted-by":"crossref","DOI":"10.2196\/12382","volume":"21","author":"P Schofield","year":"2019","unstructured":"Schofield P, Shaw T, Pascoe M. Toward comprehensive patient-centric care by integrating digital health technology with direct clinical contact in Australia. J Med Internet Res. 2019;21:e12382.","journal-title":"J Med Internet Res"},{"key":"3293_CR123","doi-asserted-by":"crossref","unstructured":"Blakey JD, Bender BG, Dima AL, Weinman J, Safioti G, Costello RW. Digital technologies and adherence in respiratory diseases: the road ahead. Eur Respir J. 2018;52:1801147.","DOI":"10.1183\/13993003.01147-2018"},{"key":"3293_CR124","first-page":"A3039","volume":"199","author":"L Hagger","year":"2019","unstructured":"Hagger L, Dutta B, J\u00f6rnten-Karlsson M. iPREDICT: transforming severe uncontrolled asthma management and patient outcomes using digital technology. Am J Respir Crit Care Med. 2019;199:A3039.","journal-title":"Am J Respir Crit Care Med"},{"key":"3293_CR125","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaip.2014.10.011","volume":"3","author":"G Mosnaim","year":"2015","unstructured":"Mosnaim G, Li H, Martin M, Richardson D, Belice PJ, Avery E, et al. A tailored mobile health intervention to improve adherence and asthma control in minority adolescents. J Allergy Clin Immunol Pract. 2015;3:288\u201390.e1.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"3293_CR126","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1513\/AnnalsATS.201509-589OT","volume":"13","author":"A Moughrabieh","year":"2016","unstructured":"Moughrabieh A, Weinert C. Rapid deployment of international tele-intensive care unit services in war-torn Syria. Ann Am Thorac Soc. 2016;13:165\u201372.","journal-title":"Ann Am Thorac Soc"},{"key":"3293_CR127","unstructured":"Deloitte Insights. Digital transformation: from a buzzword to an imperative for health systems. https:\/\/www2.deloitte.com\/us\/en\/insights\/industry\/health-care\/digital-transformation-in-healthcare.html. Accessed 29 Sep 2022."},{"key":"3293_CR128","unstructured":"National Digital Health Strategy and Framework for Action. https:\/\/www.digitalhealth.gov.au\/about-us\/strategies-and-plans\/national-digital-health-strategy-and-framework-for-action. Accessed 29 Sep 2022."},{"key":"3293_CR129","unstructured":"About Mallafi. https:\/\/malaffi.ae\/what-is-malaffi\/about-malaffi\/. Accessed 29 Sep 2022."},{"key":"3293_CR130","unstructured":"Comprehensive assessment of Oman\u2019s health information system 2019. https:\/\/applications.emro.who.int\/docs\/9789290224891-eng.pdf?ua=1. Accessed 29 Sep 2022."},{"key":"3293_CR131","unstructured":"I-SEHA program Bahrain. https:\/\/www.indracompany.com\/sites\/default\/files\/smart_i_seha.pdf. Accessed 29 Sep 2022."},{"key":"3293_CR132","unstructured":"Country score justification and references. Bahrain. https:\/\/www.ghsindex.org\/wp-content\/uploads\/2021\/12\/Bahrain.pdf. Accessed 29 Sep 2022."},{"key":"3293_CR133","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1080\/02770903.2019.1591443","volume":"57","author":"LJ Nannini","year":"2020","unstructured":"Nannini LJ. Treat to target approach for asthma. J Asthma. 2020;57:687\u201390.","journal-title":"J Asthma"},{"key":"3293_CR134","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/art.38323","volume":"66","author":"DH Solomon","year":"2014","unstructured":"Solomon DH, Bitton A, Katz JN, Radner H, Brown EM, Fraenkel L. Review: treat to target in rheumatoid arthritis: fact, fiction, or hypothesis? Arthritis Rheumatol. 2014;66:775\u201382.","journal-title":"Arthritis Rheumatol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03293-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03293-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03293-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T15:09:29Z","timestamp":1758899369000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03293-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,6]]},"references-count":134,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["3293"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03293-6","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,6]]},"assertion":[{"value":"14 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Luis Nannini was an honorary speaker for AstraZeneca. Michael G. Crooks received grants from the National Institute for Health and Care Research, AstraZeneca, Boehringer Ingelheim, Chiesi, Pfizer and Philips and consultancy fees, honoraria and\/or non-financial support from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Novartis, Orion, Pfizer and Sanofi. Pin-Kuei Fu received grants from the National Science and Technology Council and Taichung Veterans General Hospital in Taiwan and honoraria and\/or non-financial support from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Novartis and Pfizer.\u2009Ashraf Alzaabi has no conflicts to declare. Francesc Xavier Moranta Ribas has no conflicts to declare. Kittipong Maneechotesuwan has no conflicts to declare. Ashraf Hatem has no conflicts to declare. Faisal Yunus has no conflicts to declare. Jes\u00fas Javier V\u00e1zquez-Cort\u00e9s has no conflicts to declare. Walter Javier Mattarucco has served as a study investigator for AstraZeneca, GlaxoSmithKline and Novartis. He has also served on speaker bureaus for AstraZeneca. Suyapa Sosa Ferrari reports payment\/honoraria for lectures, presentations, speaker bureaus, manuscript writing or educational events from AstraZeneca, Boehringer Ingelheim and Pfizer; support for attending meetings and\/or travel from AstraZeneca, Pfizer and Novartis; participation in a Data Safety Monitoring Board or Advisory Board; and a leadership or fiduciary role in other board, society, committee or advocacy group (paid or unpaid) from ALAT, Honduras Respiratory Society and the Central American and Caribbean Pulmonary Federation. Mark Cohen-Todd reports honorarium payments for lectures from AstraZeneca, GlaxoSmithKline, Luminova\/Novartis and Boehringer Ingelheim; support for attending meetings (ALAT Congress 2024) from Luminova\/Novartis; and a leadership or fiduciary role in other board, society, committee or advocacy group (paid or unpaid) from ATS for BOD 2024\u20132025. Natalia Garcia reports honoraria or payments for lectures, presentations, speaker bureaus, manuscript writing or educational events from AstraZeneca, GlaxoSmithKline and Novartis; payment for expert testimony from SI on the use of biologicals in the Dominican Republic; participation in a Data Safety Monitoring Board or Advisory Board from AstraZeneca, GlaxoSmithKline and Luminova\/Novartis; and a leadership or fiduciary role in other board, society, committee or advocacy group (ALAT Severe Asthma Guide editor). Miguel Ant\u00fanez reports consulting fees from GlaxoSmithKline for an advisory board; payments\/honoraria for lectures from GlaxoSmithKline and AstraZeneca; and support for attending meetings from GlaxoSmithKline, AstraZeneca and Sanofi. Leonora Ca\u00f1izares-Fernandez has no conflicts to declare. Truong Le Van Ngoc has no conflicts to declare. John Mpe has no conflicts to declare. Kurtulu\u015f Aksu reports payment\/honoraria for lectures, presentations, speaker bureaus, manuscript writing or educational events from AstraZeneca, GlaxoSmithKline, Novartis, Sandoz, Chiesi, \u0130brahim Etem, Abdi \u0130brahim, Deva, Acino, Bilim, Celtis, Nobel and Roxall. Zaurbek Aisanov received payment or honoraria for lectures, presentations, speaker bureaus, manuscript writing or educational events, and support for attending meetings and\/or travel from AstraZeneca, GlaxoSmithKline, Novartis, Sandoz, Chiesi and Sanofi. Hisham Farouk is an employee of AstraZeneca.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}